Comparative Clinical Pathology

, Volume 21, Issue 6, pp 1407–1415 | Cite as

Association of IL-10 gene promoter polymorphisms and non-Hodgkin lymphoma in Egyptian patients, relation to susceptibility, correlation with survival

  • Rania M. Sami
  • Aml Soliman Nasr
  • Noha Y. Ibrahim
  • Dalia O. Darweesh
  • Noha M. El Hussieny
Original Article


The pathophysiology of non-Hodgkin’s lymphoma is still unknown. Many cytokines, including interleukin-10 (IL-10), play a role in the perpetuation of the disease. The aim of the study was to investigate the association of IL-10 gene promoter polymorphisms with non-Hodgkin lymphoma and to correlate with survival. Fifty patients with diffuse large B-cell lymphoma as well as 50 age- and sex-matched apparently healthy volunteers were genotyped for biallellic IL-10 gene promoter polymorphisms at positions −1082(A/G) and −3557(T/A) using polymerase chain reaction–restriction fragment length polymorphism. There were highly statistically significant differences between the two studied groups regarding results of IL-10 1082A/G polymorphism, for homozygous (GG) and heterozygous (AG) genotypes (p value <0.0001) but no statistically significant differences regarding homozygous (AA) genotype (p value = 0.7583). IL-10 3575T/A polymorphism revealed highly statistically significant differences between the two groups regarding homozygous (TT; p value <0.0001) and heterozygous (TA) genotypes (p value = 0.0007), but no significant difference found regarding homozygous (AA) genotype (p value = 0.1622). We did not find any associations between bad prognostic factors and any of the genotypes or alleles frequencies. Our results also reported that there was no impact of these polymorphisms on survival of lymphoma patients. IL-10 1082A/G and 3557T/A polymorphisms could be claimed as independent risk factors for susceptibility to lymphoma, regardless of any associated bad prognostic factors and without impact on overall survival.


Non-Hodgkin lymphoma Interleukin-10 Promoter polymorphisms RFLP 


  1. Benjamin D, Knobloch TJ, Dayton MA (1992) Human B-cell interleukin 10: B-cell lines derived from patients with acquired immunodeficiency syndrome and Burkitt’s lymphoma constitutively secrete large quantities of interleukin-10. Blood 80(5):1289–1298PubMedGoogle Scholar
  2. Berglund M, Thunberg U, Roos G et al (2005) The interleukin-10 gene promoter polymorphism (−1082) does not correlate with clinical outcome in diffuse large B-cell lymphoma. Blood 105(12):4894–4895PubMedCrossRefGoogle Scholar
  3. Bogunia-Kubik K, Mazur G, Wróbel T et al (2008) Interleukin-10 gene polymorphisms influence the clinical course of non-Hodgkin’s lymphoma. Tissue Antigens 71(2):146–150PubMedCrossRefGoogle Scholar
  4. Coiffier B, Gisselbrecht C, Herbrecht R et al (1989) LNH-84 regimen: a multi-center study of intensive chemotherapy in 737 patients with aggressive malignant lymphoma. J Clin Oncol 7(8):1018–1026PubMedGoogle Scholar
  5. Cunningham LM, Chapman C, Dunstan R et al (2003) Polymorphisms in the interleukin 10 gene promoter are associated with susceptibility to aggressive non-Hodgkin’s lymphoma. Leuk Lymphoma 44(2):251–255PubMedCrossRefGoogle Scholar
  6. Domingo-Domènech E, Benavente Y, González-Barca E et al (2007) Impact of interleukin-10 polymorphisms (−1082 and −3575) on the survival of patients with lymphoid neoplasms. Haematologica 92(11):1475–1481PubMedCrossRefGoogle Scholar
  7. Fernberg P, Chang ET, Duvefelt K et al (2010) Genetic variation in chromosomal translocation breakpoint and immune function genes and risk of non-Hodgkin lymphoma. Canc Causes Contr 21(5):759–769CrossRefGoogle Scholar
  8. Gibson AW, Edberg JC, Wu J et al (2001) Novel single nucleotide polymorphisms in the distal IL-10 promoter affect IL-10 production and enhance the risk of systemic lupus erythematosus. J Immunol 166(6):3915–3922PubMedGoogle Scholar
  9. Hulkkonen J, Pertovaara M, Antonen J et al (2001) Genetic association between interleukin-10 promoter region polymorphisms and primary Sjogren’s syndrome. Arthritis Rheum 44(1):176–179PubMedCrossRefGoogle Scholar
  10. Karin M, Greten FR (2005) NF-kappaB: linking inflammation and immunity to cancer development and progression. Nat Rev Immunol 5(10):749–759PubMedCrossRefGoogle Scholar
  11. Kube D, Hua TD, von Bonin F et al (2008) Effect of interleukin-10 gene polymorphisms on clinical outcome of patients with aggressive non-Hodgkin’s lymphoma: an exploratory study. Clin Canc Res 14(12):3777–3784CrossRefGoogle Scholar
  12. Lan Q, Zheng T, Rothman N et al (2006) Cytokine polymorphisms in the Th1/Th2 pathway and susceptibility to non-Hodgkin lymphoma. Blood 107(10):4101–4108PubMedCrossRefGoogle Scholar
  13. Lech-Maranda E, Baseggio L, Bienvenu J et al (2004) Interleukin-10 gene promoter polymorphisms influence the clinical outcome of diffuse large B-cell lymphoma. Blood 103(9):3529–3534PubMedCrossRefGoogle Scholar
  14. Loercher AE, Nash MA, Kavanagh JJ et al (1999) Identification of an IL-10-producing HLA-DR-negative monocyte subset in the malignant ascites of patients with ovarian carcinoma that inhibits cytokine protein expression and proliferation of autologous T cells. J Immunol 163(11):6251–6260PubMedGoogle Scholar
  15. Moore KW, de Waal Malefyt R, Coffman RL et al (2001) Interleukin 10 and the interleukin receptor. Annu Rev Immunol 19:683–765PubMedCrossRefGoogle Scholar
  16. Moraes MO, Santos AR, Schonkeren JJ et al (2003) Interleukin-10 promoter haplotypes are differently distributed in the Brazilian versus the Dutch population. Immunogenetics 54(12):896–899PubMedGoogle Scholar
  17. Mosmann TR (1994) Properties and functions of interleukin-10. Adv Immunol 56:1–26PubMedCrossRefGoogle Scholar
  18. Myers AM, Moore GE, Atkins CD (1993) A predictive model for aggressive non-Hodgkin’s lymphoma. The International non-Hodgkin’s Lymphoma Prognostic Factors Project. New Engl J Med 329(14):987–994CrossRefGoogle Scholar
  19. Oken MM, Creech RH, Tormey DC et al (1982) Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 5(6):649–655PubMedCrossRefGoogle Scholar
  20. Oswald IP, Gazzinelli RT, Sher A et al (1992) IL-10 synergizes with IL-4 and TGF-beta to inhibit macrophage cytotoxic activity. J Immunol 148(11):3578–3582PubMedGoogle Scholar
  21. Purdue MP, Lan Q, Kricker A et al (2007) Polymorphisms in immune function genes and risk of non-Hodgkin lymphoma: findings from the New South Wales non-Hodgkin Lymphoma Study. Carcinogenesis 28(3):704–712PubMedCrossRefGoogle Scholar
  22. Rasouli M, Kiany S, Behbin M (2008) Interleukin-10 gene polymorphisms and susceptibility to brucellosis in Iranian patients. Iran J Immunol 5(2):131–135PubMedGoogle Scholar
  23. Rosenberg SA (1977) Validity of the Ann Arbor staging classification for the non-Hodgkin’s lymphomas. Canc Treat Rep 61(6):1023–1027Google Scholar
  24. Rothman N, Skibola CF, Wang SS et al (2006) Genetic variation in TNF and IL10 and risk of non-Hodgkin lymphoma: a report from the InterLymph Consortium. Lancet Oncol 7(1):27–38PubMedCrossRefGoogle Scholar
  25. Salmaggi A, Eoli M, Corsini E et al (2000) Cerebrospinal fluid interleukin-10 levels in primary central nervous system lymphoma: a possible marker of response to treatment? Ann Neurol 47(1):137–138PubMedCrossRefGoogle Scholar
  26. Sato T, McCue P, Masuoka K et al (1996) Interleukin 10 production by human melanoma. Clin Canc Res 2(8):1383–1390Google Scholar
  27. Turner DM, Williams DM, Sankaran D et al (1997) An investigation of polymorphism in the interleukin-10 gene promoter. Eur J Immunogenet 24(1):1–8PubMedCrossRefGoogle Scholar
  28. Wang SS, Cerhan JR, Hartge P et al (2006) Common genetic variants in proinflammatory and other immunoregulatory genes and risk for non-Hodgkin lymphoma. Canc Res 66(19):9771–9780CrossRefGoogle Scholar
  29. Wang SS, Cozen W, Cerhan JR et al (2007) Immune mechanisms in non-Hodgkin lymphoma: joint effects of the TNF G308A and IL10 T3575A polymorphisms with non-Hodgkin lymphoma risk factors. Canc Res 67(10):5042–5054CrossRefGoogle Scholar
  30. Westendorp RG, van Dunne FM, Kirkwood TB et al (2001) Optimizing human fertility and survival. Nat Med 7(8):873PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag London Limited 2011

Authors and Affiliations

  • Rania M. Sami
    • 1
  • Aml Soliman Nasr
    • 1
    • 4
  • Noha Y. Ibrahim
    • 2
  • Dalia O. Darweesh
    • 2
  • Noha M. El Hussieny
    • 3
  1. 1.Clinical Pathology Department, Faculty of MedicineCairo UniversityCairoEgypt
  2. 2.Nuclear Medicine and Oncology Department, Faculty of MedicineCairo UniversityCairoEgypt
  3. 3.Internal Medicine Department, Faculty of MedicineCairo UniversityCairoEgypt
  4. 4.Kasr El Eini School of MedicineCairoEgypt

Personalised recommendations